ArticlePloS one2016
Cost-Effectiveness Analysis of Screening for and Managing Identified Hypertension for Cardiovascular Disease Prevention in Vietnam.
Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.
- Cost-Effectiveness of Population Screening Programs for Cardiovascular Diseases and Diabetes in Low- and Middle-Income Countries: A Systematic Review.Frontiers in public health · 2022Pooled it
- The Cost-Effectiveness of Adapting and Implementing a Brief Intervention to Target Frequent Alcohol Use Among Persons with HIV in Vietnam.AIDS and behavior · 2021Trial
- 2021 Clinical Practice Guidelines on Periodic Health Examination.Acta medica Philippina · 2026Article
- Article
- Cost-effectiveness and budget impact analysis of screening and preventive interventions for cardiovascular disease in Myanmar: an economic modelling study.The Lancet regional health. Southeast Asia · 2024Article
- Cost-utility analysis of community-based interventions for hypertension control in Vietnam.Research square · 2024Article
- Cost-Effectiveness Analysis of Personalized Hypertension Prevention.Journal of personalized medicine · 2023Article
- Addressing global disparities in blood pressure control: perspectives of the International Society of Hypertension.Cardiovascular research · 2023Article
- Cost-effectiveness of non-communicable disease prevention in Southeast Asia: a scoping review.Frontiers in public health · 2023Article
- Unmet Healthcare Needs among College Students during the COVID-19 Pandemic: Implications for System-Wide and Structural Changes for Service Delivery.Healthcare (Basel, Switzerland) · 2022Article
- Building the health-economic case for scaling up the WHO-HEARTS hypertension control package in low- and middle-income countries.Revista panamericana de salud publica = Pan American journal of public health · 2022Article
- Cost effectiveness of antihypertensive drugs and treatment guidelines.European journal of clinical pharmacology · 2021Article
- Cost-effectiveness of a Community-based Hypertension Improvement Project (ComHIP) in Ghana: results from a modelling study.BMJ open · 2021Article
- Optimal Strategy of Hypertension Screening in a Nationwide Health Examination: Early and Periodic Blood Pressure Measurement.Korean circulation journal · 2021Article
- Cost-Effectiveness Analysis of Hypertension Screening in the Korea National Health Screening Program.Korean circulation journal · 2021Article
- Cost-Effectiveness of Improved Hypertension Management in India through Increased Treatment Coverage and Adherence: A Mathematical Modeling Study.Global heart · 2021Article
- The cost-effectiveness of government actions to reduce sodium intake through salt substitutes in Vietnam.Archives of public health = Archives belges de sante publique · 2021Article
- Health screening for emerging non-communicable disease burdens among the global poor: Evidence from sub-Saharan Africa.Journal of health economics · 2021Article
- The cost-effectiveness of hypertension management in low-income and middle-income countries: a review.BMJ global health · 2020Review
- What Is the Best Mix of Population-Wide and High-Risk Targeted Strategies of Primary Stroke and Cardiovascular Disease Prevention?Journal of the American Heart Association · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo inform development of guidelines for hypertension management in Vietnam, we evaluated the cost-effectiveness of different strategies on screening for hypertension in preventing cardiovascular disease (CVD).
methodsA decision tree was combined with a Markov model to measure incremental cost-effectiveness of different approaches to hypertension screening. Values used as input parameters for the model were taken from different sources. Various screening intervals (one-off, annually, biannually) and starting ages to screen (35, 45 or 55 years) and coverage of treatment were analysed. We ran both a ten-year and a lifetime horizon. Input parameters for the models were extracted from local and regional data. Probabilistic sensitivity analysis was used to evaluate parameter uncertainty. A threshold of three times GDP per capita was applied.
resultsCost per quality adjusted life year (QALY) gained varied in different screening scenarios. In a ten-year horizon, the cost-effectiveness of screening for hypertension ranged from cost saving to Int$ 758,695 per QALY gained. For screening of men starting at 55 years, all screening scenarios gave a high probability of being cost-effective. For screening of females starting at 55 years, the probability of favourable cost-effectiveness was 90% with one-off screening. In a lifetime horizon, cost per QALY gained was lower than the threshold of Int$ 15,883 in all screening scenarios among males. Similar results were found in females when starting screening at 55 years. Starting screening in females at 45 years had a high probability of being cost-effective if screening biannually was combined with increasing coverage of treatment by 20% or even if sole biannual screening was considered.
conclusionFrom a health economic perspective, integrating screening for hypertension into routine medical examination and related coverage by health insurance could be recommended. Screening for hypertension has a high probability of being cost-effective in preventing CVD. An adequate screening strategy can best be selected based on age, sex and screening interval.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.